DOCSLIB.ORG

389 © Springer Nature Switzerland AG 2020 C. Georgiades, H. S. Kim

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
389 © Springer Nature Switzerland AG 2020 C. Georgiades, H. S. Kim Index A percutaneous ablation Ablation modalities cryoablation, 215 cryoablation, 7, 9 microwave ablation, 215 follow-up, 176 oligometastatic disease, 218, 219 irreversible electroporation, 10–12 pain palliation, 216–218 microwave ablation, 5–7 radiofrequency, 215 outcomes, 176 BRAF genes, 275 radiofrequency ablation, 3–5 Breast cancer risks and complications, 176 cryoablation, 230, 231 selection criteria and indication, 175 hyperthermic ablation technique, 175 cryoablation, 229 thermal ablation, 1, 2 HIFU, 228 Ablative or alcohol chemoembolization microwave ablation, 228 (ACE), 112 RFA, 227 Abscopal effect, 283, 374, 383 hypothermic ablation, 228 American Association of Clinical incidence, 225 Endocrinology, 245 mutations, 225 American College of Endocrinology, 245 nonthermal ablation, 231 American College of Radiology (ACR), 336 percutaneous thermal ablation of American Thyroid Association guidelines, 245 metastatic disease American Urological Association (AUA), 208 oligometastatic disease, 231, 232 Anaplastic thyroid cancers, 243, 245 palliative ablation, 232–234 Angiotensin receptor blocker (ARB), 288 PET-guided ablation, 233 Anticipated ablation zone geometry, 50 pre- and post-radioembolization, 237 Associazione Medici Endocrinologi medical radiation segmentectomy for isolated liver guidelines, 245 mass, 236 solitary lung mass ablation, 234 transarterial liver-directed therapy, 235, 237 B Bronchopleural fistula, 49, 232 Bone metastatic disease osseous augmentation peripheral skeleton augmentation, C 220, 221 Cabozantinib, 283 trans-arterial embolization, 221 Carcinoid syndrome, 182, 183 vertebral augmentation technique, Cardiovascular and Interventional Society of 219, 220 Europe, 208 © Springer Nature Switzerland AG 2020 389 C. Georgiades, H. S. Kim (eds.), Image-Guided Interventions in Oncology, https://doi.org/10.1007/978-3-030-48767-6 390 Index Celiac ganglion neurolysis E antecrural approach, 291 ELISPOT assays, 63 complications, 292 Embolization, 96 follow-up care, 292 Endoluminal biopsy technique, 310, 311 lateral decubitus position, 291 European Association of Urology, 208 neurolytic agents, 292 Exosomes, 315 outcomes, 292 External beam radiation therapy (EBRT), patient preparation, 290 121, 191 patient selection, 290 prone position, 291 recovery, 292 F supine position, 291 Fine needle aspiration biopsy, 307 Chemoembolic emulsion, 32 FOLFIRINOX, 288 Chemoembolization, 125–129 Fotemustine, 277 Circulating tumor cells (CTCs), 315 French Sarcoma Group, 262 Circulating tumor DNA (ctDNA), 314–315 Coagulative necrosis, 1 Coaxial needle technique, 308–310 G Colorectal cancer (CRC), see Liver Gastroduodenal ulcer, 133 metastatic disease Gastrointestinal stromal tumor (GIST), 267 Combined positive score (CPS), 300 Gelfoam embolization, 33 Conjunctival and adnexal melanomas, 273 Gemcitabine/nab-paclitaxel, 288 Conventional transarterial chemoembolization Gene assay, 320 (cTACE), 149, 150, 186, 267 Genitofemoral nerve, 205 angiographic evaluation, 123 Granulocyte-macrophage colony stimulating chemoembolization, 125–129 factor (GM-CSF), 282 complication, 132, 133 Ground glass opacification (GGO), 330, 333 cone-beam CT, 125 follow-up, 131 indication, 122, 123 H lipiodol-anticancer drug emulsion, 125 Heat-ablated lesions, 1 outcomes, 131 Heat shock proteins (HSPs), 375 preparation, 123 Hepatic arterial infusion chemotherapy technical considerations, 129–130 (HAIC), 141 Core needle biopsy, 308 Hepatic artery infusion (HAI), 174 Cosmesis, 226 Hepatic parenchyma, 16 Cryoablation, 7, 9, 50, 51, 54, 71, 94 Hepatocellular carcinoma (HCC), 320, 321 Cutaneous melanoma, 273, 275, 277 AASLD hepatocellular carcinoma Cytotoxic T-lymphocyte-associated antigen 4 diagnostic algorithm, 84, 86 (CTLA-4), 277 ablative or alcohol chemoembolization, 112 axial T1 fat-suppressed multi-phase D contrast-enhanced MRI, 85 Damage-associated molecular patterns BCLC stage 0 (very early) & stage (DAMPs), 375 A (early) DAXX/ATRX mutations, 322 cryoablation, 94 Dermatofibrosarcoma protuberans liver transplantation, 90, 91 (DFSP), 264 microwave ablation, 93 Desmoid tumors (desmoid-type radiofrequency ablation, 92, 93 fibromatosis), 262–264 recurrent early stage, 94 Driver mutation, 322, 324 surgical resection, 91 Drug-eluting bead (DEB) therapy, 150, 151, 337 BCLC stage B (intermediate) & stage C Drug-eluting bead trans-arterial (advanced) chemoembolization (DEB-TACE), bridging & downstaging, 95 98, 99, 134, 136 combination therapy, 107–109 Index 391 locoregional therapy (see Locoregional magnetic resonance imaging, 305 therapy) molecular profiling, 299 SBRT, 109, 110 navigation techniques and guidance systemic therapy (see Systemic systems, 306, 307 therapy) outcomes and results, 314 clinical staging, 86, 87 post-procedure management, 313 clinical surveillance, 83, 84 preprocedure care, 301, 302 curative-intent radiation segmentectomy, renal biopsy, 313 110, 111 single needle biopsy, 308 diagnosis, 84, 85 tandem needle technique, 308 epidemiology/pathophysiology, 81–83, transvenous hepatic biopsy technique, 310 119, 120 ultrasonography, 302, 303 external-beam radiation therapy, 121 Image-guided thermal ablation (IGTA), 47 hepatic arterial infusion chemotherapy, 141 Immune related adverse events (irAEs), 300 intra-arterial therapies (see intra-arterial Immune system in cancer therapies) abscopal effect, 373, 374 intra-procedural bloodflow elimination phase, 373 moduluation, 111 equilibrium phase, 373 investigational systemic therapies, 111 immune tolerance phase, 373 iodine-125, 142 immunoediting, 373 multimodality treatment, 140, 141 immunosuppression, 372 pathophysiology, 83 LRTs radiofrequency ablation, 140 for HCC, 381 surgery, role of, 120 immune checkpoint inhibitors, systemic/immuno-therapy, 121 381, 383 transarterial ethanol ablation, 142 Immunotherapy, 106 Wisconsin current treatment algorithm, 89 Interventional oncology High mobility group protein B1 ablation (HMGB1), 375 ablation modalities, 378 Human epidermal growth factor receptor 2 ablation protocol, 378 oncoprotein gene (HER2neu), 226 activating antigen-presenting cells, Hydrodissection, 227, 229 375, 377 Hyperthermic ablation, 227, 228 CD8+ T-Cells against tumor Hypothermic ablation, 228 antigens, 377 IO techniques and synergistic effects, 376 I reducing immunosuppressive Image-guided percutaneous biopsy factors, 375 C-arm cone beam CT, 303 tumorigenic effects of ablation coaxial needle technique, 308–310 modalities, 378 complications, 313, 314 tumor-specific antigens and computed tomography, 304 inflammation, 375 contraindications, 301 LRTs core needle biopsy, 308 for HCC, 381 CT fluoroscopy, 304, 305 immune checkpoint inhibitors, 380, 381 endoluminal biopsy technique, 310, 311 timing, 383 FDG-PET, 306 with immune checkpoint inhibitors, fine needle aspirate vs. core biopsy, 382 311, 312 with immune checkpoint inhibitors, in fine needle aspiration biopsy, 307 humans, 382 fluoroscopy, 303 selective intraarterial radioembolization, image guidance and selection, 302 379, 380 immune checkpoint therapy, 300 transarterial chemoembolization, 379 indications, 301 Intraarterial delivery of chemotherapy, 62 liquid biopsy techniques, 314, 315 Intraarterial/locoregional therapy, 254 392 Index Intra-arterial therapies (IAT), 16, 165 risks and complications, 176 cTACE selection criteria and indication, 175 angiographic evaluation, 123 technique, 175 chemoembolization, 125–129 hepatic artery infusion, 174 complication, 132, 133 intraarterial therapies, 165 cone-beam CT, 125 stereotactic body radiation therapy, 165 follow-up, 131 surgery, role of, 162 indication, 122, 123 systemic therapy, 162–164 lipiodol-anticancer drug emulsion, 125 transarterial chemoembolization outcomes, 131 outcomes, 173, 174 preparation, 123 risks and complications, 173 technical considerations, 129–130 selection criteria and indication, 171 DEB-TACE, 134, 136 technique, 171, 173 neuroendocrine neoplasms transarterial radioembolization indications, 185 complications, 169 radioembolization, 189, 190 follow-up, 169 TACE and TAE, 186–188 outcomes, 169, 171 radioembolization, 136 risks, 168 complications, 139 selection criteria and indication, indication, 136 165, 166 outcome, 137, 139 technique, 166–168 procedure, 136, 137 Liver tumors, LRTs Intrahepatic cholangiocarcinoma (ICC) after TACE, 338, 339 ablation therapies, 154–156 after TARE, 340, 341 intra-arterial directed therapies CT/MRI, 337 conventional transarterial cTACE vs DEB, 337 chemoembolization, 149, 150 energy-based ablation drug-eluting bead therapy, 150, 151 after cryoablation, 343 90Y, 151–153 after IRE, 343 radiation therapy, 156 after MWA, 341–343 systemic and liver directed therapies, 146, after RFA, 341, 342 149, 157 residual/recurrent tumor following LRT Ipilimumab, 278, 284 HCC, 344, 345 Irreversible electroporation (IRE), 10–12, 231 MRI, 345, 346 PET/CT, 346, 347 treatment types, 336 K Lobectomy, 45 Ki67, 322 Local consolidative therapy (LCT), 69, 70 KRAS mutation, 322 Locoregional therapies (LRTs), 231, 237 drug-eluting bead trans-arterial chemoembolization, 98, 99 L embolization, 96 Lipiodol-anticancer drug emulsion, 125 liver tumors (see Liver tumors, LRTs) Lipiodol drug emulsion, 30, 33 PCa (see Prostate cancer ablation) Liquid biopsy techniques, 314, 315 pulmonary tumor ablation (see Pulmonary Liver-directed therapy, 226, 235, 237 tumor ablation) Liver Imaging Reporting and Data System renal tumors (see Renal tumors (LI-RADS) version 2017 treatment ablation, LRTs) response (LR-TR) algorithm, 336 transarterial chemoembolization, 96–98 Liver metastatic disease
Load more

Recommended publications
  • Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: a Systematic Review for Post Mortem Applications
    diagnostics Review Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications Cristina Mondello 1,*, Elvira Ventura Spagnolo 2,*, Luigi Cardia 3 , Daniela Sapienza 1, Serena Scurria 1, Patrizia Gualniera 1 and Alessio Asmundo 1 1 Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, via Consolare Valeria, 1, 98125 Messina, Italy; [email protected] (D.S.); [email protected] (S.S.); [email protected] (P.G.); [email protected] (A.A.) 2 Section Legal Medicine, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Via del Vespro, 129, 90127 Palermo, Italy 3 IRCCS Centro Neurolesi Bonino-Pulejo, 98100 Messina, Italy; [email protected] * Correspondence: [email protected] (C.M.); [email protected] (E.V.S.); Tel.: +39-347062414 (C.M.); +39-3496465532 (E.V.S.) Received: 19 October 2020; Accepted: 31 October 2020; Published: 2 November 2020 Abstract: The complement system has a significant role in myocardial ischemia/reperfusion injury, being responsible for cell lysis and amplification of inflammatory response. In this context, several studies highlight that terminal complement complex C5b-9, also known as the membrane attack complex (MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing the characteristics of its activation in myocardial infarction. Here, a systematic literature review was reported to evaluate the principal features, advantages, and limits (regarding the application) of complement components and MAC in post mortem settings to perform the diagnosis of myocardial ischemia/infarction. The review was performed according to specific inclusion and exclusion criteria, and a total of 26 studies were identified.
    [Show full text]
  • Absolute Measurement of the Tissue Origins of Cell-Free DNA in the Healthy State and Following Paracetamol Overdose Danny Laurent1, Fiona Semple1, Philip J
    Laurent et al. BMC Medical Genomics (2020) 13:60 https://doi.org/10.1186/s12920-020-0705-2 RESEARCH ARTICLE Open Access Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose Danny Laurent1, Fiona Semple1, Philip J. Starkey Lewis2, Elaine Rose1, Holly A. Black1, Jennifer Coe1, Stuart J. Forbes2, Mark J. Arends3, James W. Dear4 and Timothy J. Aitman1* Abstract Background: Despite the emergence of cell-free DNA (cfDNA) as a clinical biomarker in cancer, the tissue origins of cfDNA in healthy individuals have to date been inferred only by indirect and relative measurement methods, such as tissue-specific methylation and nucleosomal profiling. Methods: We performed the first direct, absolute measurement of the tissue origins of cfDNA, using tissue-specific knockout mouse strains, in both healthy mice and following paracetamol (APAP) overdose. We then investigated the utility of total cfDNA and the percentage of liver-specific cfDNA as clinical biomarkers in patients presenting with APAP overdose. Results: Analysis of cfDNA from healthy tissue-specific knockout mice showed that cfDNA originates predominantly from white and red blood cell lineages, with minor contribution from hepatocytes, and no detectable contribution from skeletal and cardiac muscle. Following APAP overdose in mice, total plasma cfDNA and the percentage fraction originating from hepatocytes increased by ~ 100 and ~ 19-fold respectively. Total cfDNA increased by an average of more than 236-fold in clinical samples from APAP overdose patients with biochemical evidence of liver injury, and 18-fold in patients without biochemically apparent liver injury. Measurement of liver-specific cfDNA, using droplet digital PCR and methylation analysis, revealed that the contribution of liver to cfDNA was increased by an average of 175-fold in APAP overdose patients with biochemically apparent liver injury compared to healthy subjects, but was not increased in overdose patients with normal liver function tests.
    [Show full text]
  • Burn Wound Infec Tion Infection Is One of the Commonest Causes of Death in Burn Patients, Particularly Those with Extensive Damage
    Burn wound infec tion Infection is one of the commonest causes of death in burn patients, particularly those with extensive damage. H RODE, MB ChB, MMed (Surg), FCS (SA), FRCS (Ed) Professor Rode is Emeritus Professor of Paediatric Surgery at the Red Cross War Memorial Children’s Hospital and the University of Cape Town. He became Chief Specialist and Head of the Department in 1997. He is the past president of the South African Association of Paediatric Surgeons (SAAPS), the South African Burn Association and the Child Accident Prevention Foundation of Southern Africa. He was secretary to SAAPS, the Finance and General Purpose Committee of the Colleges of Medicine, the European Club for Paediatric Burns and the Pan-African Paediatric Surgical Association and is on the Executive Committee of the College of Surgeons. He serves on the editorial board of 3 paediatric surgical journals, has a lifetime interest in thermal injuries and has written extensively on the subject. I DO VALE, MB ChB Dr I do Vale graduated MB ChB from the University of the Witwatersrand in 2006 and is currently working as a medical officer in the Department of Surgery in the Johannesburg General Hospital. She has successfully completed the ACLS, BSS and ATLS courses as well as the primary examination from the CMSA. She wants to specialise in plastic and reconstructive surgery, focusing on congenital hand surgery, reconstruction of burn injuries and cleft palate repair. A J W MILLAR, MB ChB, FRCS (Ed), FRCS (Eng), DCH, FRACS, FCS (SA) Professor Millar qualified at the University of Cape Town with surgical training in paediatric and general surgery in the UK, the Red Cross War Memorial Children’s Hospital, and the Royal Children’s Hospital, Melbourne.
    [Show full text]
  • Insulin Enhancement of the Antitumor Activity of Chemotherapeutic Agents
    www.nature.com/scientificreports OPEN Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2 Siddarth Agrawal1*, Marta Woźniak1, Mateusz Łuc1, Sebastian Makuch1, Ewa Pielka1, Anil Kumar Agrawal2, Joanna Wietrzyk 3, Joanna Banach3, Andrzej Gamian4, Monika Pizon5 & Piotr Ziółkowski1 The present state of cancer chemotherapy is unsatisfactory. New anticancer drugs that marginally improve the survival of patients continue to be developed at an unsustainably high cost. The study aimed to elucidate the efects of insulin (INS), an inexpensive drug with a convincing safety profle, on the susceptibility of colon cancer to chemotherapeutic agents: 5-fuorouracil (FU), oxaliplatin (OXA), irinotecan (IRI), cyclophosphamide (CPA) and docetaxel (DOC). To examine the efects of insulin on cell viability and apoptosis, we performed an in vitro analysis on colon cancer cell lines Caco-2 and SW480. To verify the results, we performed in vivo analysis on mice bearing MC38 colon tumors. To assess the underlying mechanism of the therapy, we examined the mRNA expression of pathways related to the signaling downstream of insulin receptors (INSR). Moreover, we performed Western blotting to confrm expression patterns derived from the genetic analysis. For the quantifcation of circulating tumor cells in the peripheral blood, we used the maintrac method. The results of our study show that insulin- pretreated colon cancer cells are signifcantly more susceptible to commonly used chemotherapeutics. The apoptosis ratio was also enhanced when INS was administered complementary to the examined drugs. The in vivo study showed that the combination of INS and FU resulted in signifcant inhibition of tumor growth and reduction of the number of circulating tumor cells.
    [Show full text]
  • Pathological Study of Facial Eczema (Pithomycotoxicosis) in Sheep
    animals Article Pathological Study of Facial Eczema (Pithomycotoxicosis) in Sheep Miguel Fernández 1,2,* , Valentín Pérez 1,2 , Miguel Fuertes 3, Julio Benavides 2, José Espinosa 1,2 , Juan Menéndez 4,†, Ana L. García-Pérez 3 and M. Carmen Ferreras 1,2 1 Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de León, C/Prof. Pedro Cármenes s/n, E-24071 León, Spain; [email protected] (V.P.); [email protected] (J.E.); [email protected] (M.C.F.) 2 Instituto de Ganadería de Montaña (IGM), CSIC-Universidad de León, Finca Marzanas s/n, E-24346 León, Spain; [email protected] 3 Department of Animal Health, NEIKER-Basque Institute for Agricultural Research and Development, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Bizkaia, P812, E-48160 Derio, Spain; [email protected] (M.F.); [email protected] (A.L.G.-P.) 4 Area de Sistemas de Producción Animal, Servicio Regional de Investigación y Desarrollo Agroalimentario, SERIDA, E-33300 Villaviciosa, Asturias, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-987-291232 † Current address: Centro Veterinario Albéitar, E-33204 Gijón, Spain. Simple Summary: Facial eczema (FE) is a secondary photosensitization disease of farm ruminants caused by the sporidesmin A, present in the spores of the saprophytic fungus Pithomyces chartarum. This study communicates an outbreak of ovine FE in Asturias (Spain) and characterizes the local immune response that may contribute to liver damage promoting cholestasis and progression Citation: Fernández, M.; Pérez, V.; towards fibrosis and cirrhosis. Animals showed clinical signs of photosensitivity and lower gain Fuertes, M.; Benavides, J.; Espinosa, J.; Menéndez, J.; García-Pérez, A.L.; of weight, loss of wool and crusting in the head for at least 6 months after the FE outbreak.
    [Show full text]
  • Autopsy Case Report and Review of the Literature Karyna C
    Fatal Neonatal Echovirus 6 Infection: Autopsy Case Report and Review of the Literature Karyna C. Ventura, M.D., Hal Hawkins, M.D., Ph.D., Michael B. Smith, M.D., David H. Walker, M.D. Department of Pathology, University of Texas Medical Branch, Galveston, Texas CASE REPORT A full-term, healthy male neonate was delivered by caesarian section to a 26-year-old primigravida A full-term boy appropriate for his gestational age woman who had a history of fever and upper respi- was born via caesarian section to a 26-year-old G1P0 ratory tract infection. On the fourth day of life, the Latin American woman who had a medical history of a well-controlled seizure disorder for which she was neonate developed a sepsis-like syndrome, acute receiving carbamazepine. She had received regular respiratory and renal failure, and disseminated in- prenatal care, with negative prenatal serologic tests travascular coagulopathy. He died 13 days after for human immunodeficiency virus, hepatitis B virus, birth. Postmortem examination revealed jaundice, and syphilis. Two weeks before delivery, she experi- anasarca, massive hepatic necrosis, adrenal hemor- enced fever and an upper respiratory tract infection. rhagic necrosis, renal medullary hemorrhage, hem- At birth, the infant weighed 3838 g and had an Apgar orrhagic noninflammatory pneumonia, and severe score of 9. The neonate was put under an oxygen encephalomalacia. Echovirus type 6 was isolated hood, then was later slowly weaned from it. On his from blood, liver, and lungs. Although uncommon, fourth day of life, the neonate developed fever echovirus type 6 infection may produce a spectrum (38.6°C) and was observed to have decreased activity.
    [Show full text]
  • Chapter 1 Cellular Reaction to Injury 3
    Schneider_CH01-001-016.qxd 5/1/08 10:52 AM Page 1 chapter Cellular Reaction 1 to Injury I. ADAPTATION TO ENVIRONMENTAL STRESS A. Hypertrophy 1. Hypertrophy is an increase in the size of an organ or tissue due to an increase in the size of cells. 2. Other characteristics include an increase in protein synthesis and an increase in the size or number of intracellular organelles. 3. A cellular adaptation to increased workload results in hypertrophy, as exemplified by the increase in skeletal muscle mass associated with exercise and the enlargement of the left ventricle in hypertensive heart disease. B. Hyperplasia 1. Hyperplasia is an increase in the size of an organ or tissue caused by an increase in the number of cells. 2. It is exemplified by glandular proliferation in the breast during pregnancy. 3. In some cases, hyperplasia occurs together with hypertrophy. During pregnancy, uterine enlargement is caused by both hypertrophy and hyperplasia of the smooth muscle cells in the uterus. C. Aplasia 1. Aplasia is a failure of cell production. 2. During fetal development, aplasia results in agenesis, or absence of an organ due to failure of production. 3. Later in life, it can be caused by permanent loss of precursor cells in proliferative tissues, such as the bone marrow. D. Hypoplasia 1. Hypoplasia is a decrease in cell production that is less extreme than in aplasia. 2. It is seen in the partial lack of growth and maturation of gonadal structures in Turner syndrome and Klinefelter syndrome. E. Atrophy 1. Atrophy is a decrease in the size of an organ or tissue and results from a decrease in the mass of preexisting cells (Figure 1-1).
    [Show full text]
  • Tissue Responses and Wound Healing Following Laser Scleral Microporation for Presbyopia Therapy
    Article Tissue Responses and Wound Healing following Laser Scleral Microporation for Presbyopia Therapy Yu-Chi Liu1–3, Brad Hall4, Nyein Chan Lwin1, Ericia Pei Wen Teo1,GaryHinFaiYam1,3, AnnMarie Hipsley4, and Jodhbir S. Mehta1–3 1 Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapore 2 Singapore National Eye Centre, Singapore 3 Duke-NUS Medical School, Singapore 4 Ace Vision Group, Inc., Newark, CA, USA Correspondence: Jodhbir S. Mehta, Purpose: To investigate the postoperative inflammatory and wound-healing responses Singapore National Eye Centre, 11 after laser scleral microporation for presbyopia. Third Hospital Avenue, Singapore Methods: 168751. e-mail: Thirty porcine eyes were used for the optimization of laser intensities first. [email protected] Six monkeys (12 eyes) received scleral microporation with an erbium yttrium aluminum garnet (Er:YAG) laser, and half of the eyes received concurrent subconjunctival colla- Received: June 6, 2019 gen gel to modulate wound-healing response. The intraocular pressure (IOP) and the Accepted: December 27, 2019 laser ablation depth were evaluated. The animals were euthanized at 1, 6, and 9 months Published: March 9, 2020 postoperatively. The limbal areas and scleras were harvested for histologic analysis and Keywords: presbyopia; laser; scleral immunofluorescence of markers for inflammation (CD11b and CD45), wound healing wound healing (CD90, tenascin-C, fibronectin, and HSP47), wound contractionα ( –smooth muscle actin [α-SMA]), vascular response (CD31), nerve injury (GAP43), and limbal stem cells (P63 and Citation: Liu Y-C, Hall B, Lwin NC, Teo telomerase). EPW, Yam GHF, Hipsley A, Mehta JS. Tissue responses and wound healing Results: In the nonhuman primate study, there was a significant reduction in IOP after following laser scleral microporation the procedure.
    [Show full text]
  • Observation and Mechanism Study of Bladder Wound Healing After Transurethral Holmium Laser Resection of Bladder Tumor
    Lasers in Medical Science (2019) 34:1217–1227 https://doi.org/10.1007/s10103-018-02713-0 ORIGINAL ARTICLE Observation and mechanism study of bladder wound healing after transurethral holmium laser resection of bladder tumor Sha Han1 & Kai Dong2 & Mengjun Shen2 & Xingjie Wang2 & Wanzi Jiang3 & Wei Zhao2,4 & Dongliang Xu2,4,5 Received: 8 August 2018 /Accepted: 26 December 2018 /Published online: 22 February 2019 # Springer-Verlag London Ltd., part of Springer Nature 2019 Abstract This research aims to observe and compare the wound healing process of urethral bladder after transurethral holmium laser resection of bladder tumor (HoLRBT) and transurethral resection of bladder tumor (TURBT) and explore the possible mechanism of wound healing and bladder re-epithelialization after HoLRBT. An animal model of canine achieving HoLRBT and TURBT was established. Cystoscopy was performed at different time points (3 days and 1, 2, 3, and 4 weeks) after operation to observe the wound healing and re-epithelialization of bladder epithelium. Bladder mucosa specimens were obtained and histopathological changes of the bladder epithelium were observed under light microscope after HE staining. Immunochemistry was used to determine the cell expression ofCK5, CK14, EGF, EGFR; microRNA expressions of CK5, CK14, EGF, and EGFR were measured by qRT-PCR. The changes of urinary EGF concentration were detected by ELISA. The bladder epithelial wound was repaired and re-epithelialized at 1 week after HoLRBT. At the 4th week, the bladder wound was basically completed and re-epithelialized; repair of bladder epithelial wounds recapitulates the wounds with the proliferation and migration of residual epithelial cells under the wound and the bladder epithelium that proliferates alongside the wound surface to complete re-epithelialization.
    [Show full text]
  • 1 Guidelines for Immune Analysis
    Guidelines for immune analysis following FUS treatment Clinical Rationale ..................................................................................................................................... 3 General Recommendations ........................................................................................................ 4 General considerations ........................................................................................................... 4 Design of analyses .................................................................................................................. 4 Analyses routes ...................................................................................................................... 4 Analysis Recommendations ....................................................................................................... 7 Analysis of tissue samples ...................................................................................................... 7 Staining (tumors, in order of priority) ................................................................................ 7 Tumor RNAseq .................................................................................................................. 7 Tumor Genetics including TMB analysis .......................................................................... 8 Phenotypic analysis of leukocytes ...................................................................................... 8 Functional assays ...............................................................................................................
    [Show full text]
  • Lung, Epithelium – Necrosis
    Lung, Epithelium – Necrosis Figure Legend: Figure 1 Lung, Bronchiole, Epithelium, Bronchiole - Necrosis in a female B6C3F1/N mouse from a subchronic study. The epithelial cells are fragmented, with pyknotic and karyorrhectic nuclei. Figure 2 Lung, Epithelium - Necrosis in a male Wistar Han rat from a chronic study. There is a large area of coagulative necrosis surrounded by suppurative inflammation. Figure 3 Lung, Epithelium, Alveolus - Necrosis in a female F344/N rat from a subchronic study. There is loss of epithelial cells, and many of the interstitial cells have pyknotic nuclei. Figure 4 Lung, Epithelium, Alveolus - Necrosis in a female F344/N rat from a subchronic study. In this focal lesion, there is loss of epithelial and interstitial cells. Comment: Necrosis (Figure 1, Figure 2, Figure 3, and Figure 4) and degeneration are considered to be parts of the continuum of cell damage, with necrosis representing irreversible cell damage and 1 Lung, Epithelium – Necrosis degeneration representing reversible cell damage. The light microscopic features of necrosis include nuclear pyknosis, karyorrhexis, or karyolysis, cell swelling, loss of cellular detail, cell fragmentation, and cytoplasmic hypereosinophilia (in which the cytoplasm often has a homogeneous appearance). Large areas of necrosis (Figure 2, Figure 3, and Figure 4) may also have disrupted tissue architecture, large areas of necrotic debris, loss of staining intensity, and inflammatory cells. Necrosis of the epithelial cells lining the airways as a result of toxic injury is often characterized by sloughing of necrotic cells or cellular debris into the lumen. The light microscopic hallmarks of reversible cell damage include cellular swelling, cytoplasmic vacuolation, perinuclear clear spaces, formation of cytoplasmic blebs, loss of normal apical blebs from Clara cells, and loss of cilia.
    [Show full text]
  • Leading Article - Hepatology Series
    Gut 1994; 35: 577-581 577 Gut Gut: first published as 10.1136/gut.35.5.577 on 1 May 1994. Downloaded from Leading article - Hepatology series Liver cell death: patterns and mechanisms This review discusses the causes and mechanisms of hepato- human liver morphogenesis. Substantial cell death is part cyte cell death in normal and diseased states, and briefly and parcel of normal embryonic development,5 yet the describes the responses ofthe liver to the inflicted damage. In human liver arising as an outgrowth of endodermal epithe- tissues such as the epidermis and gastrointestinal mucosa, lium from the primitive foregut, is conspicuous -for its cells proliferate, differentiate, and die in a highly ordered and lack of overt cell death during morphogenesis. predictable fashion.' In these tissues, cells destined for terminal differentiation proceed through a short series of cell divisions to amplify their numbers, before permanently Cell death: necrosis and apoptosis decycling from the proliferative cell cycle and migrating into In 1980, Wytlie et a16 proposed a new classification of cell an anatomically distinct differentiated compartment, which death based on morphological criteria, which separated the heralds their imminent demise. Such a tissue hierarchy is a degradative reactions that occur after cell death resulting feature of the so called continually renewing tissues such as from generally severe perturbations (necrosis), from a gene http://gut.bmj.com/ gut, epidermis, and bone marrow, while liver with its almost directed programme
    [Show full text]